-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, ABndyFaAqdfX5w+8l38Asi40+VT4aGr5hq5XcD2+LuBXaysz/SDP+7xlOplQn9iR IAlSzUDMk2Ku9mCUHnzUZQ== 0000812796-06-000049.txt : 20070316 0000812796-06-000049.hdr.sgml : 20070316 20060818150327 ACCESSION NUMBER: 0000812796-06-000049 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20060818 FILER: COMPANY DATA: COMPANY CONFORMED NAME: DOR BIOPHARMA INC CENTRAL INDEX KEY: 0000812796 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 411505029 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 1101 BRICKELL AVENUE STREET 2: SUITE 701 S CITY: MIAMI STATE: FL ZIP: 33131 BUSINESS PHONE: 305-534-3383 MAIL ADDRESS: STREET 1: 1101 BRICKELL AVENUE STREET 2: SUITE 701 S CITY: MIAMI STATE: FL ZIP: 33131 FORMER COMPANY: FORMER CONFORMED NAME: ENDOREX CORP DATE OF NAME CHANGE: 19960916 FORMER COMPANY: FORMER CONFORMED NAME: IMMUNOTHERAPEUTICS INC DATE OF NAME CHANGE: 19920703 CORRESP 1 filename1.htm DOR Extension letter
DOR BioPharma, Inc.


August 18, 2006

SENT VIA EDGAR

Amy C. Buckner
Staff Accountant
Division of Corporation Finance
United States Securities and Exchange Commission
100 F Street, NE
Washington, D.C. 20549

RE: Review of Filings and comments related to Form 10KSB for the Fiscal Year Ended December 31, 2005 and Form 10QSB for the Fiscal Quarter Ended June 30, 2006.

Dear Ms. Buckner,

Thank you for the opportunity to work with you and discuss the disclosure requirements. This letter is in response to your letter dated August 15, 2006. We are requesting that the response date be extended to September 8, 2006. Currently, we are in the process of moving the offices and expect to be in the new offices by early next week; in addition our auditors are on an audit in Boston and will not be fully accessible until next week.

If you should have any questions please call me at 305-534-3383.

Sincerely,


/s/ Evan Myrianthopoulos_
Evan Myrianthopoulos
Chief Financial Officer
DOR BioPharma, Inc.

MD/AMEX/EC

 -----END PRIVACY-ENHANCED MESSAGE-----